FDA advisory committee recommends not approving Trevena pain drug

A Food and Drug Administration advisory committee, in a close vote, recommended not approving a new drug application submitted by Trevena Inc. for its experimental pain medicine Olinvo.

The vote by the federal agency’s Anesthetic and Analgesic Drug Products Advisory Committee was eight against, and seven in favor of, supporting the approval of the application.

The FDA is not required to follow the recommendations of its advisory panels, though it typically does.

“We continu e to believe that…

Source: bizjournals.com Health Care:Physician Practices headlines - October 12, 2018 Category: American Health Authors: John George Source Type: news